Skip to main content
editorial
. 2019 Sep 3;101(4):727–728. doi: 10.4269/ajtmh.19-0568

Table 1.

Effect of liposomal amphotericin B (L-AmB) on VL, CL, and ML: representative studies

Study No. Disease (Leishmania species) Endemic region L-AmB regimen Total dose No. of patients % Cure (month assessed) Ref.
1 VL (L. donovani) Indian subcontinent AmB (deoxycholate) 1 mg/kg qod × 15 injs 15 mg/kg 108 96.3 (6 months) 1
2 VL (L. donovani) Indian subcontinent 10 mg/kg × 1 inj 10 mg/kg 304 95.7 (6 months) 1
3 VL (L. donovani) Indian subcontinent 10 mg/kg × 1 inj 10 mg/kg 1,143 94 (12 months) 2
4 VL (L. donovani) East Africa 10 mg/kg × 1 inj 10 mg/kg 40 58 (6 months) 4
3 mg/kg × 7 injs over 21 days 21 mg/kg 54 85 (6 months) 4
5 VL (L. infantum) Europe 1–1.4 mg/kg/day × 21 days 21–29 mg/kg 10 100 (12 months) 5
3 mg/kg/day × 10 days 30 mg/kg 10 100 (12 months) 5
6 VL (L. chagasi) Brazil 3 mg/kg/day × 7 days 21 mg/kg 109 87 (6 months) 7
7 VL (L. chagasi) Brazil 2 mg/kg/day × 7 injs over 10 days 14 mg/kg 13 62 (6 months) 8
8 CL (L. tropica) Old World 3 mg/kg on days 1–5 and 10 18 mg/kg 13 84 (11 months) 12
9 CL (L. braziliensis) New World 3 mg/kg on days 1–5 and 10 18 mg/kg 34 97 (2 years) 13
10 ML New World Not available 30–35 mg/kg 16 88 (1 year) 15
11 PKDL Indian subcontinent (2 courses of) 5 mg/kg qod × 4 injs 40 mg/kg 4 100 17
12 PKDL Indian subcontinent 3 mg/kg × 5 injs over 15 days 15 mg/kg 273 78 (12 months) 18

CL = cutaneous leishmaniasis; injs = injections; ML = mucosal leishmaniasis; qod = every other day; PKDL = post–kala-azar dermal leishmaniasis; VL = visceral leishmaniasis.